Literature DB >> 2667593

Electrocardiographic evidence of myocardial salvage after thrombolysis in acute myocardial infarction.

K J Hogg1, K R Lees, R S Hornung, C A Howie, F G Dunn, W S Hillis.   

Abstract

There is a need for a simple clinical measurement that will indicate the extent of myocardial salvage after successful thrombolysis. This study examined whether coronary artery reperfusion reduced the infarct size as assessed electrocardiographically after thrombolytic treatment. The sum of the (sigma) ST segment area in leads showing ST segment elevation in the 12 lead electrocardiogram at presentation was used as an index of potential myocardial injury (initial ischaemic index). The evolved infarct size at 48 h was assessed by a QRS scoring system. Two groups of patients, both admitted with anterior myocardial infarction within 6 h of onset, were studied. Group 1 (n = 35) received analgesia only and group 2 (n = 33) received thrombolytic treatment either by the intracoronary (streptokinase, n = 13) or intravenous route (anistreplase, n = 20). Reperfusion was assessed angiographically. The mean (SD) potential infarct size assessed by the initial ischaemic index was similar in both groups (group 1, sigma ST area = 115 (60) mm2 and group 2 = 126 (77 mm2). The QRS score representing evolved infarct size was significantly lower in the treated group (4.1 (2.5] than in group 1 (7.8 (2.6]. The 95% confidence intervals for QRS scores based on the admission sigma ST area from patients with successful reperfusion were applied to a third set of patients (n = 22) to test the ability of the admission ST area (myocardial injury) to predict the QRS score accurately. While patients with successful reperfusion had significantly lower QRS scores than those who did not (4.5 (3.1) versus 9.3 (3.4)), the wide confidence intervals caused by inter-individual variability precluded an accurate prediction of the QRS score in an individual from the sigma ST area at time of presentation. There was no difference in infarct size in patients treated early (</= 3 h) (QRS score 4.2(2.8)) or later (3-6 h) (4.1(2.1)). This study provides evidence that sequential electrocardiographic changes are reduced in patients with anterior infarction who achieve reperfusion after thrombolytic treatment and that this benefit is shown with treatment given up to six hours after infarct onset. None the less, the relation between the initial ischaemic index and the evolved QRS score has wide confidence intervals, reflecting inter-individual variability, and does not allow the prediction of a QRS score in an individual patient.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2667593      PMCID: PMC1216704          DOI: 10.1136/hrt.61.6.489

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  27 in total

1.  Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials.

Authors:  S Yusuf; R Collins; R Peto; C Furberg; M J Stampfer; S Z Goldhaber; C H Hennekens
Journal:  Eur Heart J       Date:  1985-07       Impact factor: 29.983

2.  The western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. A 12-month follow-up report.

Authors:  J W Kennedy; J L Ritchie; K B Davis; M L Stadius; C Maynard; J K Fritz
Journal:  N Engl J Med       Date:  1985-04-25       Impact factor: 91.245

3.  A randomized trial of intracoronary streptokinase in the treatment of acute myocardial infarction.

Authors:  J L Anderson; H W Marshall; B E Bray; J R Lutz; P R Frederick; F G Yanowitz; F L Datz; S C Klausner; A D Hagan
Journal:  N Engl J Med       Date:  1983-06-02       Impact factor: 91.245

4.  Effect of intravenous streptokinase on acute myocardial infarction: pooled results from randomized trials.

Authors:  M J Stampfer; S Z Goldhaber; S Yusuf; R Peto; C H Hennekens
Journal:  N Engl J Med       Date:  1982-11-04       Impact factor: 91.245

5.  Effect of interventions in salvaging left ventricular function in acute myocardial infarction: a study of intracoronary streptokinase.

Authors:  F H Sheehan; D G Mathey; J Schofer; H J Krebber; H T Dodge
Journal:  Am J Cardiol       Date:  1983-09-01       Impact factor: 2.778

6.  Acute non-Q wave myocardial infarction associated with early ST segment elevation: evidence for spontaneous coronary reperfusion and implications for thrombolytic trials.

Authors:  B L Huey; M Gheorghiade; R S Crampton; G A Beller; D L Kaiser; D D Watson; T W Nygaard; G B Craddock; S L Sayre; R S Gibson
Journal:  J Am Coll Cardiol       Date:  1987-01       Impact factor: 24.094

7.  Return of left ventricular function after reperfusion in patients with myocardial infarction: importance of subtotal stenoses or intact collaterals.

Authors:  W J Rogers; W P Hood; J A Mantle; W A Baxley; J K Kirklin; G L Zorn; H P Nath
Journal:  Circulation       Date:  1984-02       Impact factor: 29.690

8.  Ventricular function and infarct size: the Western Washington Intravenous Streptokinase in Myocardial Infarction Trial.

Authors:  J L Ritchie; M Cerqueira; C Maynard; K Davis; J W Kennedy
Journal:  J Am Coll Cardiol       Date:  1988-04       Impact factor: 24.094

9.  Influence of infarct artery patency on the relation between initial ST segment elevation and final infarct size.

Authors:  R A Hackworthy; M B Vogel; P J Harris
Journal:  Br Heart J       Date:  1986-09

10.  Reliability of Q-wave formation and QRS score in predicting regional and global left ventricular performance in acute myocardial infarction with successful reperfusion.

Authors:  F L Mikell; J Petrovich; M C Snyder; G J Taylor; H W Moses; J T Dove; J E Batchelder; J A Schneider; H A Wellons
Journal:  Am J Cardiol       Date:  1986-04-15       Impact factor: 2.778

View more
  1 in total

1.  Enhanced thrombolytic efficacy and reduction of infarct size by simultaneous infusion of streptokinase and heparin.

Authors:  G Melandri; A Branzi; F Semprini; V Cervi; N Galiè; B Magnani
Journal:  Br Heart J       Date:  1990-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.